133 related articles for article (PubMed ID: 38555235)
1. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract][Full Text] [Related]
2. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.
Arnold P; Penaloza-Ramos MC; Adedokun L; Rees S; Lockhat M; Spary L; Watkins A; Gnanapragasam V; Crabb SJ
Sci Rep; 2021 Nov; 11(1):22151. PubMed ID: 34772971
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis.
Hird AE; Dvorani E; Saskin R; Emmenegger U; Herschorn S; Kodama R; Kulkarni GS; Nam RK
Clin Genitourin Cancer; 2023 Apr; 21(2):e27-e34. PubMed ID: 36371403
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study.
Wang Y; Liu C; Liu C; Lu Y; Ban L; Niu Y
J Med Econ; 2024; 27(1):361-369. PubMed ID: 38375556
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
10. Management of nonmetastatic castration-resistant prostate cancer.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):366-371. PubMed ID: 30015690
[TBL] [Abstract][Full Text] [Related]
11. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
Saad F; Bögemann M; Suzuki K; Shore N
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):323-334. PubMed ID: 33558665
[TBL] [Abstract][Full Text] [Related]
12. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Schultz NM; O'Day K; Sugarman R; Ramaswamy K
J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
[TBL] [Abstract][Full Text] [Related]
14. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
[TBL] [Abstract][Full Text] [Related]
15. Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Schultz NM; Janjan N; George DJ
Future Oncol; 2023 Oct; 19(31):2075-2082. PubMed ID: 37646326
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
[TBL] [Abstract][Full Text] [Related]
17. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U; Hussain M; Shore N; Fizazi K; Tombal B; Penson D; Saad F; Efstathiou E; Madziarska K; Steinberg J; Sugg J; Lin X; Shen Q; Sternberg CN
Eur J Cancer; 2021 Dec; 159():237-246. PubMed ID: 34784577
[TBL] [Abstract][Full Text] [Related]
18. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
[TBL] [Abstract][Full Text] [Related]
19. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
